SEC Form 4 · accession 0001209191-18-031802
Clearside Biomedical, Inc. · CLSD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Clay Thorp
Director · 10% Owner
Period of report
May 17, 2018
Accepted (ET)
May 21, 2018 · 4:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001539029
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3,F4 | May 17, 2018 | S | 100,000 | $13.03 | D | 3,527,533 | I | See Footnotes |
| Common StockF5,F6,F3,F4 | May 18, 2018 | S | 61,139 | $13.16 | D | 3,466,394 | I | See Footnotes |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Consists of (i) 3,000 shares sold by Hatteras NC Fund, LP ("Hatteras NC"), (ii) 38,300 shares sold by Hatteras Venture Partners III, LP ("HVP III"), (iii) 3,500 shares sold by Hatteras Venture Affiliates III, LP ("HVA III"), (iv) 6,200 shares sold by Hatteras Venture Partners IV, LP ("HVP IV") and (v) 49,000 shares sold by Hatteras Venture Partners IV SBIC, LP ("HVP IV SBIC").
- F2This transaction was executed in multiple trades at prices ranging from $12.23 to $13.37, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
- F3The reporting person is one of the general partners of: (i) Hatteras Venture Advisors III, LLC, the general partner of HVP III and HVA III; (ii) Hatteras Venture Advisors IV SBIC, LLC, the general partner of HVP IV SBIC; and (iii) Hatteras Venture Advisors IV, LLC, the general partner of HVP IV and Hatteras NC. HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC are the record holders of the securities, and the reporting person may be deemed to share voting and dispositive power over the securities held by HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC.
- F4The reporting person disclaims beneficial ownership of these securities and this report is not an admission that the reporting person is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.
- F5Consists of (i) 1,737 shares sold by Hatteras NC, (ii) 23,497 shares sold by HVP III, (iii) 2,108 shares sold by HVA III, (iv) 3,791 shares sold by HVP IV and (v) 30,006 shares sold by HVP IV SBIC.
- F6This transaction was executed in multiple trades at prices ranging from $12.97 to $13.41, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.